| 品牌 |
产品编号
(生产商编号) |
产品名称 | 等级 | 规格 | 零售价(RMB) | CAS No. |
|
Adipogen
------------------ - |
AG-44B-0011-KI01 |
- | 1 Set |
5,400.00
|
- | |
|
Adipogen
------------------ - |
AG-44B-0012-KI01 |
- | 1 Set |
5,880.00
|
- | |
|
Adipogen
------------------ - |
AG-44B-0013-KI01 |
- | 1 Set |
5,880.00
|
- | |
|
RevMab
------------------ - |
REV-31-1307-00-C100 |
- | 100 µg |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1322-00-C100 |
- | 100 µg |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1323-00-C100 |
- | 100 µg |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1324-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1328-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1329-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1330-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1331-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1332-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1333-00-R100 |
- | 100 µl |
5,730.00
|
- | |
|
RevMab
------------------ - |
REV-31-1334-00-R100 |
anti-EGFR (phospho Y1068) (human), Rabbit Monoclonal (RM443) |
- | 100 µl |
5,730.00
|
- |
|
RevMab
------------------ - |
REV-31-1335-00-R100 |
anti-Detyrosinated alpha-Tubulin (human), Rabbit Monoclonal (RM444) |
- | 100 µl |
5,730.00
|
- |
|
RevMab
------------------ - |
REV-54-1306-00-C100 |
anti-SARS-CoV-2 Nucleocapsid Chimeric Human, Rabbit Monoclonal (RMH03) |
- | 100 µg |
5,730.00
|
- |
|
Fabgennix
------------------ - |
FGX-PBTK-BIOTIN |
- | 100 µg |
咨询 |
- | |
|
AIST
------------------ - |
634-29181 |
3,5-Bis(trifluoromethyl)benzoic Acid for Quantitative NMR (1H, 19F) |
- | 200 mg |
咨询 |
725-89-3 |
|
AIST
------------------ - |
639-44151 |
1,4-Bis(trimethylsilyl)-2,3,5,6-tetrafluorobenzene for Quantitative NMR(1H,19F) |
- | 100 mg |
咨询 |
16956-91-5 |
|
FUJIFILM Wako
------------------ 和光纯药 |
011-28013 |
for Immunochemistry | 10uL |
咨询 |
- |




